SK10912000A3 - Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie - Google Patents

Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie Download PDF

Info

Publication number: SK10912000A3
Authority: SK; Slovakia
Prior art keywords: morpholinol; compound; chlorophenyl; trimethyl; formula
Prior art date: 1998-01-21

Application number

SK1091-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Phillip Frederick Morgan

David Lee Musso

John Joseph Partridge

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-21

Filing date

1999-01-20

Publication date

2001-04-09

1998-01-21 Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en

1999-01-20 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-04-09 Publication of SK10912000A3 publication Critical patent/SK10912000A3/sk

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Epidemiology (AREA)
Psychology (AREA)
Diabetes (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK1091-2000A 1998-01-21 1999-01-20 Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie SK10912000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9801230.5A GB9801230D0 (en)	1998-01-21	1998-01-21	Pharmaceutically active morpholinol
US7218098P	1998-01-22	1998-01-22
PCT/US1999/001134 WO1999037305A1 (en)	1998-01-21	1999-01-20	Pharmaceutically active morpholinol

Publications (1)

Publication Number	Publication Date
SK10912000A3 true SK10912000A3 (sk)	2001-04-09

Family

ID=26312986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1091-2000A SK10912000A3 (sk)	1998-01-21	1999-01-20	Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie

Country Status (30)

Country	Link
US (2)	US6274579B1 (hu)
EP (2)	EP1829544A1 (hu)
JP (1)	JP2002501025A (hu)
KR (1)	KR100568063B1 (hu)
CN (2)	CN1203858C (hu)
AP (1)	AP1229A (hu)
AT (1)	ATE365042T1 (hu)
AU (1)	AU755536B2 (hu)
BR (1)	BR9907203A (hu)
CA (1)	CA2318268A1 (hu)
CY (1)	CY1106828T1 (hu)
DE (1)	DE69936335T2 (hu)
DK (1)	DK1047428T3 (hu)
EA (1)	EA002410B1 (hu)
EE (1)	EE04452B1 (hu)
ES (1)	ES2288012T3 (hu)
HR (2)	HRP20000494B1 (hu)
HU (1)	HUP0100900A3 (hu)
ID (1)	ID26334A (hu)
IL (2)	IL161942A0 (hu)
IS (1)	IS2494B (hu)
NO (2)	NO326878B1 (hu)
NZ (3)	NZ520349A (hu)
PL (1)	PL193622B1 (hu)
PT (1)	PT1047428E (hu)
SG (1)	SG115489A1 (hu)
SK (1)	SK10912000A3 (hu)
TR (1)	TR200002126T2 (hu)
WO (1)	WO1999037305A1 (hu)
YU (1)	YU67102A (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7098206B2 (en) *	1998-01-21	2006-08-29	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6998400B2 (en) *	1998-01-22	2006-02-14	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
EP1051164A1 (en)	1998-01-29	2000-11-15	Sepracor, Inc.	Pharmacological uses of pure (+) -bupropion
CA2318920A1 (en)	1998-01-29	1999-08-05	James W. Young	Pharmaceutical uses of optically pure (-)-bupropion
US6855820B2 (en)	1999-01-20	2005-02-15	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6734213B2 (en)	1999-01-20	2004-05-11	Smithkline Beecham Corporation	Pharmaceutically active morpholinol
US6342496B1 (en) *	1999-03-01	2002-01-29	Sepracor Inc.	Bupropion metabolites and methods of use
US6337328B1 (en) *	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use
AU7750100A (en) *	1999-10-13	2001-04-23	Glaxo Group Limited	Method for the treatment of obesity
GB0003232D0 (en) *	2000-02-11	2000-04-05	Smithkline Beecham Plc	Novel composition
CA2365428C (en) *	2000-12-21	2008-10-21	Brasscorp Limited	Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en)	2001-12-31	2005-12-27	R.J. Doran & Co. LTD	LED inspection lamp
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
KR20110043664A (ko) *	2002-05-17	2011-04-27	듀크 유니버시티	비만치료방법
ATE413882T1 (de) *	2002-08-23	2008-11-15	Lilly Co Eli	2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
GB0219687D0 (en) *	2002-08-23	2002-10-02	Lilly Co Eli	Benzyl morpholine derivatives
CA2522708C (en) *	2003-04-29	2013-05-28	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
WO2005042503A1 (en) *	2003-10-27	2005-05-12	Smithkline Beecham Corporation	Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s, 3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof
GB0325055D0 (en) *	2003-10-27	2003-12-03	Smithkline Beecham Corp	New process
GB0326148D0 (en) *	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
GB0327195D0 (en) *	2003-11-21	2003-12-24	Smithkline Beecham Corp	Novel use
GB0327619D0 (en) *	2003-11-27	2003-12-31	Smithkline Beecham Corp	New use
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007517901A (ja)	2004-01-13	2007-07-05	デューク・ユニバーシティー	体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
RU2006139930A (ru) *	2004-05-03	2008-06-10	Дюк Юниверсити (Сша/Сша) (Us)	Составы для содействия снижению веса
FI117283B (fi)	2005-02-04	2006-08-31	Kone Corp	Hissijärjestelmä
ES2761812T3 (es)	2005-11-22	2020-05-21	Nalpropion Pharmaceuticals Inc	Composición y métodos de aumento de la sensibilidad a la insulina
WO2007079470A2 (en) *	2006-01-03	2007-07-12	Algebra, Inc.	Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
KR101971218B1 (ko)	2006-11-09	2019-08-27	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
US20090075994A1 (en) *	2007-09-14	2009-03-19	Protia, Llc	Deuterium-enriched radafaxine
WO2009158114A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
WO2010121022A1 (en)	2009-04-15	2010-10-21	Research Triangle Institute	Monoamine reuptake inhibitors
EP2523557B1 (en)	2010-01-11	2019-09-25	Nalpropion Pharmaceuticals, Inc.	Methods of providing weight loss therapy in patients with major depression
WO2011146821A2 (en)	2010-05-21	2011-11-24	Research Triangle Institute	1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
EP2571858B1 (en)	2010-05-21	2018-06-20	Research Triangle Institute	Phenylmorpholines and analogues thereof
US9510405B2 (en)	2011-06-30	2016-11-29	Schneider Electric Industries Sas	Dual power SMPS for a modular lighting system
CN102670617B (zh) *	2012-04-13	2013-03-20	湖南大学	布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
PT2858640T (pt)	2012-06-06	2020-06-30	Nalpropion Pharmaceuticals Llc	Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
CN105949142B (zh) *	2016-05-21	2018-03-27	南华大学	具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) *	2021-06-17	2021-12-30	Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ)	Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US170430A (en) *		1875-11-30		Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) *	1984-07-05	1984-08-08	Wellcome Found	Heterocyclic pharmaceutical compounds
GB9108629D0 (en)	1991-04-23	1991-06-12	Wellcome Found	Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en)	1999-03-01	2002-01-08	Sepracor, Inc.	Bupropion metabolites and methods of use

1999
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2328099A (en)	1999-08-09
EP1047428A1 (en)	2000-11-02
DE69936335T2 (de)	2008-02-28
NO20003721D0 (no)	2000-07-20
CY1106828T1 (el)	2012-05-23
NO326878B1 (no)	2009-03-09
PL193622B1 (pl)	2007-02-28
US20020019396A1 (en)	2002-02-14
SG115489A1 (en)	2005-10-28
ES2288012T3 (es)	2007-12-16
EP1047428A4 (en)	2001-12-19
AP1229A (en)	2003-12-04
NZ505809A (en)	2002-09-27
WO1999037305A1 (en)	1999-07-29
NZ520349A (en)	2004-02-27
PT1047428E (pt)	2007-09-07
CN1203858C (zh)	2005-06-01
CN1294513A (zh)	2001-05-09
EE04452B1 (et)	2005-04-15
DE69936335D1 (de)	2007-08-02
DK1047428T3 (da)	2007-10-08
IS2494B (is)	2009-02-15
US6274579B1 (en)	2001-08-14
CN1255389C (zh)	2006-05-10
HUP0100900A2 (hu)	2002-05-29
JP2002501025A (ja)	2002-01-15
IL161942A0 (en)	2005-11-20
HRP20000494B1 (en)	2009-02-28
ATE365042T1 (de)	2007-07-15
EA200000691A1 (ru)	2001-04-23
AU755536B2 (en)	2002-12-12
KR100568063B1 (ko)	2006-04-07
KR20010034285A (ko)	2001-04-25
PL342012A1 (en)	2001-05-07
ID26334A (id)	2000-12-14
HUP0100900A3 (en)	2002-08-28
IS5568A (is)	2000-07-20
HRP20000494A2 (en)	2000-12-31
YU67102A (sh)	2004-12-31
CN1528753A (zh)	2004-09-15
IL137346A0 (en)	2001-07-24
CA2318268A1 (en)	1999-07-29
AP2000001869A0 (en)	2000-09-30
NZ529316A (en)	2004-05-28
EA002410B1 (ru)	2002-04-25
HRP20051024A2 (hr)	2006-04-30
EP1829544A1 (en)	2007-09-05
TR200002126T2 (tr)	2000-12-21
EE200000438A (et)	2001-12-17
BR9907203A (pt)	2000-10-17
NO20083529L (no)	2000-09-19
US6391875B2 (en)	2002-05-21
NO20003721L (no)	2000-09-19
EP1047428B1 (en)	2007-06-20

Publication	Publication Date	Title
SK10912000A3 (sk)	2001-04-09	Farmaceuticky prijateľné soli a solváty (+)-(2s,3s)-2-(3-chlórfenyl)-3,5,5-trimetyl-2-morfolinolu, farmaceutický prostriedok s ich obsahom a ich použitie
Robertson et al.	1988	The absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor
FR2611707A1 (fr)	1988-09-09	Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament
US20230150936A1 (en)	2023-05-18	Analogs of n,n,n-trimethyl-4-phosphoryloxytryptamine
SK9002001A3 (en)	2002-04-04	5ht1 antagonists for antidepressant therapy
US6855820B2 (en)	2005-02-15	Pharmaceutically active morpholinol
US6734213B2 (en)	2004-05-11	Pharmaceutically active morpholinol
US6998400B2 (en)	2006-02-14	Pharmaceutically active morpholinol
US7098206B2 (en)	2006-08-29	Pharmaceutically active morpholinol
AU2002315922B2 (en)	2006-06-01	Pharmaceutically active morpholinol
CZ20002690A3 (cs)	2000-12-13	Farmaceuticky přijatelné soli a solváty (+)- (2S,3S)-2-(3-chlorfenyl)-3,5,5-trimethyl-2- morfolinolu a farmaceutický prostředek
EP1761262B1 (en)	2008-12-03	Marine compounds with calcium channel blocking properties for the treatment of cognitive or neurodegenerative diseases
HK1107521A (en)	2008-04-11	Pharmaceutically active morpholinol
MXPA00007127A (en)	2001-07-09	Pharmaceutically active morpholinol
KR20040023653A (ko)	2004-03-18	제약상 활성인 모르폴리놀